Evidence map›Paper›PMID 42004053›Full record

ArticleAmerican journal of cancer research2026

THAP7-AS1 orchestrates IGF2BP3-m

Qiuyan Li, Junjie Bai, Shiwen Zheng, Jiaxuan Liao, Zesong Yang, Wanghai Cai, Jiexiang Lin, Liefu Ye

Abstract read
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qiuyan LiShengli Clinical College of Fujian Medical University Fuzhou 350001, Fujian, P. R. China.
Junjie BaiShengli Clinical College of Fujian Medical University Fuzhou 350001, Fujian, P. R. China.
Shiwen ZhengDepartment of Laboratory Medicine, West China Xiamen Hospital, Sichuan University Xiamen 361022, Fujian, P. R. China.
Jiaxuan LiaoShengli Clinical College of Fujian Medical University Fuzhou 350001, Fujian, P. R. China.
Zesong YangShengli Clinical College of Fujian Medical University Fuzhou 350001, Fujian, P. R. China.
Wanghai CaiShengli Clinical College of Fujian Medical University Fuzhou 350001, Fujian, P. R. China.
Jiexiang LinShengli Clinical College of Fujian Medical University Fuzhou 350001, Fujian, P. R. China.
Liefu YeShengli Clinical College of Fujian Medical University Fuzhou 350001, Fujian, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphatic dissemination is a major cause of treatment failure in muscle-invasive bladder cancer (MIBC), yet the RNA circuits linking post-transcriptional regulation to lymphatic metastasis remain incompletely defined. Here, we identify THAP7-AS1 as a predominantly cytoplasmic long noncoding RNA that is markedly upregulated in lymph node (LN) metastatic bladder cancer (BCa) and is associated with poor clinical outcome. Functionally, THAP7-AS1 promotes invasion and transendothelial migration in vitro and enhances LN metastasis in vivo. Mechanistically, THAP7-AS1 interacts with the m

Indexed as

CCN2IGF2BP3Lymphatic metastasisN6-methyladenosine (m6A)THAP7-AS1

Identifiers

PMID42004053
PMCPMC13090477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.